Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1141-1160 of 2,120 trials

Recurrent Solid Tumors: OBT076 Treatment Study

We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.

Malignant Solid Tumor1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Macular Telangiectasia Type 1: Aflibercept vs. Placebo

We are studying whether aflibercept can improve retinal thickness and vision in patients with macular telangiectasia type 1 compared to a placebo. The trial also looks at the safety of the treatment.

Macular Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesOphthalmology

COPD Exacerbation: New Diagnostic Strategy

We are testing a new method using advanced diagnostics to see if it can help reduce antibiotic use during severe COPD flare-ups. This study compares this approach to standard treatment to evaluate its effectiveness and safety.

Severe COPD with Ventilation Support>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPulmonology

Pancreatic Cancer: FOLFOX vs. Gemcitabine

We are comparing two chemotherapy treatments, FOLFOX and gemcitabine, for patients with advanced pancreatic cancer who cannot tolerate a stronger regimen. The goal is to see which treatment works better and is safer for these patients.

Pancreatic Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Carcinoid Syndrome: Paltusotine Treatment Study

We are evaluating the safety and how the body processes different doses of paltusotine in people with carcinoid syndrome. This study aims to ensure the treatment is safe and well-tolerated.

Carcinoid Syndrome3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Diffuse Cutaneous Systemic Sclerosis: Ianalumab Study

We are testing a new medication, ianalumab, for people with diffuse cutaneous systemic sclerosis. The goal is to see if it improves symptoms and lung function compared to a placebo.

Systemic Scleroderma>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Postoperative Pain Relief After Hip Surgery: Intrathecal Morphine Study

We are testing whether intrathecal morphine, with or without a specific nerve block, can improve pain relief after total hip arthroplasty. This study aims to find the best way to manage pain during recovery.

Total Hip Replacement Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Non-Hodgkin Lymphoma: New CAR T-Cell Therapy Study

We are comparing a new point-of-care CAR T-cell treatment to a standard commercial option for patients with relapsed or refractory Non-Hodgkin Lymphoma. The goal is to see if the new therapy can improve survival and safety outcomes.

Relapsed/Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: WVE-006 Treatment

We are testing a new treatment called WVE-006 for people with Pi*ZZ Alpha-1 Antitrypsin Deficiency. The study aims to evaluate its safety and how the body responds to it.

Alpha-1 Antitrypsin Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyGastroenterologyHepatologyInternal MedicinePulmonology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Atezolizumab for Muscle-Invasive Bladder Cancer

We are studying whether atezolizumab can help patients with muscle-invasive bladder cancer who cannot have surgery after chemo-radiotherapy. The trial looks at how well it works and its impact on patients' quality of life.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Colorectal Cancer: STC-1010 Immunotherapy

We are studying a new immunotherapy for patients with advanced colorectal cancer that cannot be surgically removed. The trial aims to evaluate its safety and effectiveness alongside standard treatment options.

Unresectable Locally Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Heart Procedure: Protamine Use in Aortic Valve Replacement

We are studying whether protamine can help reduce major bleeding and ischemic events in patients after transcatheter aortic valve replacement. This trial also examines other safety factors and complications related to the procedure.

Transcatheter Aortic Valve Replacement (TAVR)>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Progressive Vitiligo: Anifrolumab and Phototherapy Study

We are investigating whether combining anifrolumab with phototherapy helps adults with progressive vitiligo regain skin color better than phototherapy alone. The study will also assess the safety and tolerability of this new treatment approach.

Vitiligo6-12 monthsEfficacy phase (II)Standard MedicinesAllergologyDermatology

Prostate Cancer: Re-treatment with [177Lu]Lu-PSMA

We are studying the effects of re-treating men with metastatic castration-resistant prostate cancer using [177Lu]Lu-PSMA. This trial aims to see if this treatment can help improve survival and quality of life.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Head and Neck Cancer: Cetuximab with Chemotherapy

We are studying a combination of cetuximab and chemotherapy followed by immunotherapy for patients with recurrent or metastatic head and neck cancer. The goal is to see if this treatment improves survival and response rates for those with a specific PD-L1 score.

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Cancer Imaging: [18F]AlF-FAPI-74 PET/CT

We are studying a new imaging method for patients with newly diagnosed esophagogastric and pancreatic cancers. This trial aims to see if it detects cancer better than current imaging techniques.

Pancreatic CancerEsophagogastric AdenocarcinomaGastric Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Haemophilia A: Efanesoctocog Alfa Treatment Study

We are investigating how efanesoctocog alfa affects joint health in patients with haemophilia A. The study aims to understand improvements in joint swelling and overall health during treatment.

Haemophilia A1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOrthopedics and Traumatology

Neurocritical Patients: Inhalation vs. Intravenous Sedation

We are studying whether inhalation sedation with isoflurane is more effective and safer than conventional intravenous sedation for patients in critical neurological care. This trial will help us understand the best sedation methods for these patients.

Pain ReliefMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology